Middleton, Steven
Hoffmann‐La Roche, Inc. New York
3 papers on CoChat
Most cited papers
- Verified
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology
Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways
Cited by 571
- Verified
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
Phelps, D., Bondra, K., Seum, S., Chronowski, C., Leasure, J., Kurmasheva, R. T., Middleton, S., Wang, D., Mo, X., & Houghton, P. J. (2015) · Pediatric Blood & Cancer
Cancer-related Molecular PathwaysSarcoma Diagnosis and Treatment
Cited by 27
- Verified
Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2012) · Blood
Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free